Exact Sciences (NASDAQ:EXAS) is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.
Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development. In 2019, the company completed the acquisition of Genomic Health, bringing Oncotype DX® diagnostic tests into its offerings. These tests assess gene expression profiles in breast, prostate and other cancers to help guide treatment decisions, furthering Exact’s mission to advance precision oncology.
Exact Sciences sells its products primarily in the United States and has extended its reach into selected international markets, including Europe and Australia. The company operates a network of laboratories and works closely with healthcare providers, payers and policy makers to support the adoption of its screening and diagnostic technologies. Exact Sciences also invests in clinical trials and real-world evidence studies to validate and refine its assays.
Kevin Conroy, who joined Exact Sciences in 2015 and became president and chief executive officer in 2017, leads the company’s efforts to integrate molecular diagnostics into standard cancer care. Under his leadership, Exact has grown its commercial infrastructure and doubled down on research initiatives aimed at developing next-generation tests for multiple tumor types. The company remains focused on improving patient outcomes through earlier detection and more personalized treatment pathways.
